Literature DB >> 1383414

A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.

S Kaye1, C Loveday, R S Tedder.   

Abstract

An assay for the analysis of point mutations in DNA fragments amplified by the polymerase chain reaction is described. The method was applied to the analysis of mutations leading to single amino acid changes in the reverse transcriptase gene of human immunodeficiency virus type-1 that are associated with decreased sensitivity of the virus to the effects of the nucleoside analogue zidovudine. The assay uses a microtitre format allowing large numbers of clinical samples to be analysed, and is a quantitative assay giving information on the relative proportions of wild-type and mutant sequence at the point being analysed. The analysis of mutations in codons 67, 70, 215, and 219 of the RT gene in samples taken at various time points after the commencement of zidovudine therapy shows a high variability in the rate at which these mutations arise and in the proportions of wild-type and mutant sequences observed. The method we describe has wide application to the analysis of other point mutations in clinical or research studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383414     DOI: 10.1002/jmv.1890370402

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  25 in total

Review 1.  HIV drug resistance: genotypic assays and their possible applications.

Authors:  A L Ballard; P A Cane; D Pillay
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

Review 2.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.

Authors:  J Goudsmit; A De Ronde; D D Ho; A S Perelson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.

Authors:  R S Tedder; S Kaye; C Loveday; I V Weller; D Jeffries; J Norman; J Weber; M Bourelly; R Foxall; A Babiker; J H Darbyshire
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

5.  Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.

Authors:  R E Edelstein; D A Nickerson; V O Tobe; L A Manns-Arcuino; L M Frenkel
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

6.  Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial.

Authors: 
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

7.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

Authors:  M D de Jong; J Veenstra; N I Stilianakis; R Schuurman; J M Lange; R J de Boer; C A Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.

Authors:  L M Frenkel; L E Wagner; S M Atwood; T J Cummins; S Dewhurst
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.